| Followers | 374 |
| Posts | 5388 |
| Boards Moderated | 1 |
| Alias Born | 05/09/2013 |
Wednesday, August 03, 2016 3:05:58 PM
I've still got LABD (bear-short biotech) on watch in regards to a Swing trade daily chart type of strategy... and I have been on sidelines since last week on ORPN, yet also I do have ORPN on watch for re-entry eventually.
LABD has been a flippable-day trade stock from Monday thru approx Tuesday (20-21's to 22-23's), but so far that's all it's proved. Still watching LABD for swing trade entry intent.
I was tempted the last couple days on LABD, but I'm still waiting to determine an entry point (for an intended daily chart swing trade).
An Important basic technical to keep in mind:
If the 20.50 (or 20+ approx) area holds on LABD yet past today thru this week yet, then it will likely be a good supportive sign for it and means market might be ready for an August correction lower.
Otherwise, in the mean time I'm not underestimating the bulls ability to resume uptrend a while yet on XBI(LABU) & stock market overall.
LABD has been a flippable-day trade stock from Monday thru approx Tuesday (20-21's to 22-23's), but so far that's all it's proved. Still watching LABD for swing trade entry intent.
I was tempted the last couple days on LABD, but I'm still waiting to determine an entry point (for an intended daily chart swing trade).
An Important basic technical to keep in mind:
If the 20.50 (or 20+ approx) area holds on LABD yet past today thru this week yet, then it will likely be a good supportive sign for it and means market might be ready for an August correction lower.
Otherwise, in the mean time I'm not underestimating the bulls ability to resume uptrend a while yet on XBI(LABU) & stock market overall.
Recent ENLV News
- Form F-3 - Registration statement by foreign private issuers • Edgar (US Regulatory) • 04/21/2026 08:15:57 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/21/2026 12:32:01 PM
- Enlivex Announces Second Regulatory Approval for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis • GlobeNewswire Inc. • 04/21/2026 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/08/2026 12:33:27 PM
- Ondo Global Markets Tokenizes Enlivex’s Ordinary Shares • GlobeNewswire Inc. • 04/08/2026 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/26/2026 12:32:01 PM
- Rain Launches an OpenClaw and AI Agent Interface Allowing Anyone To Create A Prediction Market Via A Single Prompt • GlobeNewswire Inc. • 03/26/2026 12:30:00 PM
- Enlivex shares jump after earnings as treasury gains boost results • IH Market News • 03/25/2026 03:05:33 PM
- Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] • Edgar (US Regulatory) • 03/25/2026 12:40:17 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/25/2026 12:31:00 PM
- Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48 • GlobeNewswire Inc. • 03/25/2026 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/24/2026 12:34:59 PM
- Enlivex Announces $21 Million Debt Financing, Decentralized Prediction Markets RAIN Token-Related Updates and $20 Million Share Repurchase Program • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/23/2026 12:02:14 PM
- Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis • GlobeNewswire Inc. • 03/23/2026 12:00:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/20/2026 08:05:23 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 11:14:20 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/13/2026 08:17:47 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/23/2026 01:00:15 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/10/2026 01:02:52 PM
- New Listing of the RAIN Token on Kraken, the Second-Largest U.S. Cryptocurrency Exchange • GlobeNewswire Inc. • 02/10/2026 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/05/2026 12:50:49 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/26/2026 01:01:50 PM
- Listing of the RAIN Token on WhiteBIT, a Leading Cryptocurrency Exchange • GlobeNewswire Inc. • 01/26/2026 01:00:00 PM
